Dainippon Sumitomo Pharma To Set Up the Regenerative & Cellular Medicine Office
Osaka, Japan, August 9, 2013 ----- Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan; President: Masayo Tada) today announced that it will set up the Regenerative & Cellular Medicine Office on September 9, 2013.
Regenerative and cellular medicine such as one involving iPS cells is identified as the new business field in the R&D strategy under the DSP's third Mid-term Business Plan (FY2013 - 2017). We are committed to exploring opportunities in this area from a mid- to long-term perspective with a view to making it one of our strong business areas supported by a number of innovative products.
The Regenerative & Cellular Medicine Office is created as a unit at the corporate level with the mandate to promote dynamically the R&D and business development in the regenerative and cellular medicine field including those based on iPS cell technology. The new Office will exercise integrated control over a variety of functions (e.g.; global strategy, R&D, and manufacturing) in DSP organizations as they pertain to regenerative and cellular medicine.
In a related move, the following personnel changes will take place in key positions on the same date.
|New position (Sept.9, 2013)||Current position||Name|
|Director, Regenerative & Cellular Medicine Office||Director, Global Strategy||Toru Kimura|
|Director, Global Strategy||Deputy Director, Global Strategy||Koichi Kozuki|
Two research groups that will belong to the Regenerative & Cellular Medicine Office will be based within the major biomedical innovation cluster located on the Kobe Port Island in Kobe City. Ease of access to leading-edge knowledge and information in the field is expected.